Business

Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

TORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the &#...

articleArch Biopartners, Inc.May 22, 20265/company/arch-biopartners-inc/news/arch-biopartners-announces-royal-columbian-hospital-has-dosed-its-first-patient-in-its-phase-ii-cardiac-surgery-associated-aki-trial
Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial

About this update from Arch Biopartners, Inc.

[{"type":"text","content":"Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial\nTORONTO, May 22, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has dosed its first patient in the Company’s ongoing Phase II trial evaluating LSALT peptide as a new drug to prevent acute kidney injury (AKI) in patients undergoing on-pump cardiac surgery (CS). Royal Columbian Hospital, located in New Westminster and part of Fraser Health, is the fourth site to dose patients in Canada. Patient recruitment into the trial is ongoing at Toronto General Hospital, part of University Health Network, St. Michael’s Hospital, part of Unity Health Toronto, and the University of Calgary, Cumming School of Medicine. “Royal Columbian Hospital dosing its first patient is another meaningful step forward for the Company’s Phase II CS-AKI trial,” said Richard Muruve, CEO of Arch Biopartners. “Arch continues to make steady progress toward the goals of the study and establishing LSALT peptide as a new drug to reduce the incidence of AKI and the need for dialysis and kidney transplants.” To increase clinical awareness of LSALT peptide and further expand the trial, the Company is in feasibility discussions with leading cardiac surgery centres in Canada and the United States, including four prospective sites in the United States and one additional site in Ontario. About Fraser Health and Royal Columbian Hospital Fraser Health provides health care services in a large region of British Columbia, including New Westminster. Serving more than one in three British Columbians, Fraser Health is focused on improving the health and well-being of over two million people in 20 diverse municipalities across the region. More than 50,000 staff, medical staff, and volunteers support health service delivery in hospitals and communities. Royal Columbian Hospital (RCH), part of Fraser Health, provides highly specialized acute care services such as tertiary trauma, cardiac surgery, neurosurgery, interventional cardiology, and thoracic surgery. These services often require the care of multiple medical specialists, multidisciplinary care teams, and the ...

More updates from Arch Biopartners, Inc.